Antibody-drug conjugates: beyond current approvals and potential future strategies
The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high...
Main Authors: | Siddharth Menon, Sagun Parakh, Andrew M. Scott, Hui K. Gan |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2022-04-01
|
Series: | Exploration of Targeted Anti-tumor Therapy |
Subjects: | |
Online Access: | https://www.explorationpub.com/Journals/etat/Article/100282 |
Similar Items
-
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
by: Sagun Parakh, et al.
Published: (2021-12-01) -
Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01) -
Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
by: Suheil Albert Atallah-Yunes, et al.
Published: (2022-01-01) -
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
by: Waqqas Tai, et al.
Published: (2022-03-01) -
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
by: Yurou Chu, et al.
Published: (2021-06-01)